Kingstown Capital Management’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

Kingstown Capital Management’s Portfolio PEARW Stock Details PEARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-200,000	Closed	-$158K	–	67
2022 Q1	$158K	Sell	200,000 -185,000	-48%	-$129K	0.24%	23
2021 Q4	$231K	Hold	385,000	–	–	0.29%	35
2021 Q3	$366K	Buy	385,000 +10,000	+3%	+$10.4K	0.37%	31
2021 Q2	$555K	Buy	+375,000	New	+$327K	0.33%	51

Other funds holding PEARW

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

OCAM

Owl Creek Asset Management New York $1.21B AUM 169.99% 1-Year Est. Return

AGC

Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return

Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

Advisory Research Chicago, Illinois $1B AUM 50.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

SRF

Silver Rock Financial Los Angeles, California $46.4M AUM 13.94% 1-Year Est. Return

Kingstown Capital Management's PEARW Position: Q2 2022 in Review

Kingstown Capital Management sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q2 2022, closing a stake of 200,000 shares — an estimated $158K sold.

Kingstown Capital Management first reported a position in PEARW in Q2 2021 and held it in 4 quarters. The position peaked at $555K in Q2 2021. 36 funds tracked by Wall St. Rank hold PEARW as of Q2 2022.

Kingstown Capital Management reported no remaining Pear Therapeutics, Inc. Warrant position as of Q2 2022 after selling out during the quarter.
Kingstown Capital Management sold 200,000 Pear Therapeutics, Inc. Warrant shares in Q2 2022, an estimated $158K.
Kingstown Capital Management first reported a position in Pear Therapeutics, Inc. Warrant in Q2 2021 and held it in 4 quarters.
Kingstown Capital Management's Pear Therapeutics, Inc. Warrant position peaked at $555K in Q2 2021.
36 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q2 2022.

Based on Kingstown Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.